Investors focused on the Medical space have likely heard of ANI Pharmaceuticals (ANIP), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of our Medical group, which includes 849 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANIP is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.39% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIP has gained about 53.91% so far this year. Meanwhile, the Medical sector has returned an average of 5.47% on a year-to-date basis. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Looking more specifically, ANIP belongs to the Medical - Biomedical and Genetics industry, which includes 355 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have gained about 8.97% so far this year, so ANIP is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ANIP. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research